Abbott UltiSynq Lead Wins FDA Approval And CE Mark
The UltiSynq lead pairs pacing and defibrillation in a single lead built for left bundle branch area pacing, a first for ICD therapy.
One lead now does the pacing and the shocking.
Abbott's UltiSynq lead won FDA approval and a CE Mark on November 10. It's the first defibrillation lead purpose-built for left bundle branch area pacing, so one lead can pace the heart's own wiring and deliver a shock.
The design answers a gap in conduction system pacing. Doctors increasingly pace through the left bundle branch because it keeps the ventricles beating in sync, but the leads built for that job couldn't defibrillate, and patients who needed an ICD often gave the approach up.
Abbott built UltiSynq on its Optisure lead platform, with true bipolar sensing and pacing. The FDA had already granted the device breakthrough designation before the approval landed.
The ASCEND CSP trial tested the lead in 205 implant attempts. Doctors succeeded in 202 of the cases, a 98.5 percent rate, and 86 percent of patients reached left bundle branch pacing or likely left bundle branch pacing, with the rest reaching left ventricular septal pacing.
Safety readouts ran to three months. The major complication-free rate was 97.5 percent at that mark, defibrillation testing succeeded in all 120 patients who completed it, and no lead repositioning was required to achieve the shock.
The market is large. Abbott counts about 150,000 ICD implants a year in the United States and about 140,000 in Europe, and the CE Mark opens the European side of that market to the new lead.
The evidence so far is short-term. ASCEND measured implant success and pacing capture at three months, not survival or lead durability over years, so the case for UltiSynq rests on early performance while the long-term record builds.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.